Under the agreement, Fuji will participate in specific early-stage research and development projects of Richter, including the recently acquired Celmatix portfolio as well as the FMC2 project of FimmCyte AG. In the framework of the co-development agreements Fuji will contribute to the R&D expenses and will obtain rights to develop, manufacture, and commercialize the product candidates subject to this agreement in Japan, the ASEAN countries, and South Korea.

Dr. Péter Turek, Head of Women’s Healthcare Business Unit at Richter, commented: “Partnering has always been instrumental to the success of Richter, and Fuji is a renowned and relaible partner in advancing innovation in women’s healthcare. Having Fuji on board not only supports the commercialization of these potential breakthrough therapies, but also enables us to share the risk and cost of early-stage developments, thereby paving the way to further expand the depth and breadth our original R&D pipeline.

About Richter

Richter aspires to be a global innovator in some key scientific fields, while dedicated to making medicines more accessible worldwide. Founded in 1901, headquartered in Hungary, with a market capitalization of EUR 4.8bn and sales of EUR 2.3bn in 2025, it operates Central Europe's largest R&D hub. Its research drives breakthroughs in Neuropsychiatry and Women's Healthcare, while Biotechnology and General Medicines strengthen its affordable treatment portfolio. Committed to sustainable growth, Richter invests in R&D, manufacturing excellence, and digitalization to advance medical innovation. Learn more at www.gedeonrichter.com

About Fuji Pharma Co., Ltd.

Fuji Pharma is a Japan-based pharmaceutical company listed on the Tokyo Stock Exchange (TSE), mainly engaged in the manufacture and sale of prescription-based pharmaceutical products. Fuji has focused on women’s healthcare since its establishment in 1965, offering a wide range of pharmaceuticals that address female‑specific conditions such as dysmenorrhea, endometriosis, menopausal disorders, infertility, and contraception. Alongside women’s healthcare, the company also positions the biosimilar business as a strategic priority and continues to expand its product lineup to provide new treatment options for patients and healthcare professionals. Fuji is committed to contributing to society where everyone can enjoy better health and well-being through the provision of high‑quality pharmaceutical products. 

For more information, visit https://www.fujipharma.jp

For further information:

Investors:        Róbert Réthy, CFA                                                                +36 20 342 2555 

Media:               Zsuzsa Beke                                                                           +36 20 916 4507